Equities

Emmaus Life Sciences Inc

EMMA:QBB

Emmaus Life Sciences Inc

Actions
  • Price (USD)0.0291
  • Today's Change-0.001 / -3.17%
  • Shares traded3.77k
  • 1 Year change-75.79%
  • Beta6.3715
Data delayed at least 15 minutes, as of Nov 13 2024 20:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Emmaus Life Sciences Inc grew revenues 60.94% from 18.39m to 29.60m while net income improved from a loss of 10.63m to a smaller loss of 3.73m.
Gross margin95.48%
Net profit margin-26.32%
Operating margin-2.84%
Return on assets-13.79%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, Emmaus Life Sciences Inc increased its cash reserves by 26.03%, or 526.00k. Cash Flow from Financing totalled 2.48m or 8.37% of revenues. In addition the company used 1.50m for operations while cash used for investing totalled 432.00k.
Cash flow per share-0.0656
Price/Cash flow per share--
Book value per share-0.8927
Tangible book value per share-0.8927
More ▼

Balance sheet in USDView more

Emmaus Life Sciences Inc uses little or no debt in its capital structure.
Current ratio0.1408
Quick ratio0.1153
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.